PE20200699A1 - Composiciones sinergicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporcion no racemica - Google Patents
Composiciones sinergicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporcion no racemicaInfo
- Publication number
- PE20200699A1 PE20200699A1 PE2019002444A PE2019002444A PE20200699A1 PE 20200699 A1 PE20200699 A1 PE 20200699A1 PE 2019002444 A PE2019002444 A PE 2019002444A PE 2019002444 A PE2019002444 A PE 2019002444A PE 20200699 A1 PE20200699 A1 PE 20200699A1
- Authority
- PE
- Peru
- Prior art keywords
- dimiracetam
- racemic
- proportion
- compositions including
- pyrrolo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Referida a una composicion que comprende los enantiomeros de (R)-3,6,7,7a-tetrahidro-1H-pirrolo[1,5-a]imidazol-2,5-diona ((R)-dimiracetam (1)) y (S)-3,6,7,7a-tetrahidro-1H-pirrolo[1,5-a]imidazol-2,5-diona ((S)-dimiracetam (2)) y/o solvatos o co-cristales farmaceuticamente aceptables de los mismos; en donde un exceso enantiomerico (ee) del (R)-dimiracetam (1) es igual o mayor a 33% y menor que o igual a 54%, en donde la proporcion de (R)-dimiracetam (1) con respecto a (S)-dimiracetam (2) es de 2:1 a 3.3:1. Dicha composicion exhibe una mayor potencia farmacologica (efecto sinergico) que sus correspondientes enantiomeros individuales o racemato; siendo util en el tratamiento y/o prevencion de una enfermedad o trastorno seleccionado preferiblemente de neuropatia sensorial periferica, dolor neuropatico periferico, convulsiones, afecciones psiquiatricas, depresion o deterioro cognitivo
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17173760 | 2017-05-31 | ||
PCT/EP2018/064125 WO2018219977A1 (en) | 2017-05-31 | 2018-05-30 | Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20200699A1 true PE20200699A1 (es) | 2020-06-23 |
Family
ID=59053899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2019002444A PE20200699A1 (es) | 2017-05-31 | 2018-05-30 | Composiciones sinergicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporcion no racemica |
Country Status (32)
Country | Link |
---|---|
US (2) | US10738054B2 (es) |
EP (2) | EP3735971A1 (es) |
JP (2) | JP6810983B2 (es) |
KR (1) | KR102269493B1 (es) |
CN (1) | CN110719779B (es) |
AU (1) | AU2018276382B2 (es) |
BR (1) | BR112019025006A2 (es) |
CA (1) | CA3061274C (es) |
CL (1) | CL2019003503A1 (es) |
CO (1) | CO2019013212A2 (es) |
CY (1) | CY1123386T1 (es) |
DK (1) | DK3534898T3 (es) |
EA (1) | EA201992817A1 (es) |
EC (1) | ECSP19085426A (es) |
ES (1) | ES2825498T3 (es) |
GE (1) | GEP20227336B (es) |
HR (1) | HRP20201608T1 (es) |
HU (1) | HUE050981T2 (es) |
IL (1) | IL270833B (es) |
JO (1) | JOP20190251A1 (es) |
LT (1) | LT3534898T (es) |
MX (1) | MX2019013897A (es) |
NI (1) | NI201900122A (es) |
PE (1) | PE20200699A1 (es) |
PH (1) | PH12019502580B1 (es) |
PT (1) | PT3534898T (es) |
RS (1) | RS60957B1 (es) |
SG (1) | SG11201909720SA (es) |
SI (1) | SI3534898T1 (es) |
UA (1) | UA125703C2 (es) |
WO (1) | WO2018219977A1 (es) |
ZA (1) | ZA201906863B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190251A1 (ar) * | 2017-05-31 | 2019-10-21 | Metys Pharmaceuticals AG | تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية |
MX2021006243A (es) * | 2018-12-04 | 2021-08-11 | Metys Pharmaceuticals AG | Composiciones sinergicas que comprenden (r)-2-(2-oxopirrolidin-1-i l)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporcion no racemica. |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1233860B (it) | 1988-02-08 | 1992-04-21 | Isf Spa | Derivati del peridroazacicloalca (1,2-a) imidazolo ad attivita' nootropa |
US5200406A (en) | 1988-02-08 | 1993-04-06 | I.S.F. Societa Per Azioni | Pharmaceutically useful 2,5-dioxo-1H-octahydroimidazo[1,2-A]azepines |
GB9123641D0 (en) | 1991-11-07 | 1992-01-02 | Isf Spa | Process |
AU1400100A (en) * | 1998-12-02 | 2000-06-19 | Darwin Discovery Limited | Therapeutic product and its use |
EP1034826A1 (en) | 1999-03-05 | 2000-09-13 | Reuter Chemische Apparatebau | Co-crystallization process |
ITMI20030573A1 (it) | 2003-03-24 | 2004-09-25 | Nikem Research Srl | Composti ad azione nootropica, loro preparazione, |
WO2008073381A2 (en) * | 2006-12-11 | 2008-06-19 | University Of Kentucky Research Foundation | Synergistic effects of combinations of nornicotine and opioids for the treatment of pain |
AU2012201853B2 (en) | 2007-04-16 | 2013-06-27 | Neurotune Ag | Use of dimiracetam in the treatment of chronic pain |
ITMI20070770A1 (it) | 2007-04-16 | 2008-10-17 | Brane Discovery S R L | Impiego di dimiracetam nel trattamento del dolore cronico |
EP2215073A4 (en) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS |
EP2098526B1 (en) | 2008-02-22 | 2014-01-15 | Neurotune AG | Nitrogen-containing bicyclic compounds active on chronic pain conditions |
US9125898B2 (en) | 2008-11-14 | 2015-09-08 | Neurotune Ag | Acetam derivatives for pain relief |
ES2473271T3 (es) | 2010-07-26 | 2014-07-04 | Neurotune Ag | Proceso de preparación de dimiracetam |
WO2012055057A1 (en) | 2010-10-29 | 2012-05-03 | Neurotune Ag | Therapeutic use of dimiracetam to prevent the hand & foot syndrome caused by sorafenib |
WO2015010217A1 (en) * | 2013-07-24 | 2015-01-29 | Neurotune Ag | Dimiracetam in the treatment of depression |
JOP20190251A1 (ar) | 2017-05-31 | 2019-10-21 | Metys Pharmaceuticals AG | تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية |
-
2017
- 2017-06-16 JO JOP/2019/0251A patent/JOP20190251A1/ar unknown
-
2018
- 2018-05-30 HU HUE18728356A patent/HUE050981T2/hu unknown
- 2018-05-30 PT PT187283569T patent/PT3534898T/pt unknown
- 2018-05-30 EP EP20181525.5A patent/EP3735971A1/en not_active Withdrawn
- 2018-05-30 GE GEAP201815251A patent/GEP20227336B/en unknown
- 2018-05-30 MX MX2019013897A patent/MX2019013897A/es active IP Right Grant
- 2018-05-30 DK DK18728356.9T patent/DK3534898T3/da active
- 2018-05-30 JP JP2020516950A patent/JP6810983B2/ja active Active
- 2018-05-30 CN CN201880034236.3A patent/CN110719779B/zh active Active
- 2018-05-30 UA UAA201911923A patent/UA125703C2/uk unknown
- 2018-05-30 SI SI201830125T patent/SI3534898T1/sl unknown
- 2018-05-30 BR BR112019025006-9A patent/BR112019025006A2/pt not_active Application Discontinuation
- 2018-05-30 ES ES18728356T patent/ES2825498T3/es active Active
- 2018-05-30 RS RS20201220A patent/RS60957B1/sr unknown
- 2018-05-30 SG SG11201909720S patent/SG11201909720SA/en unknown
- 2018-05-30 LT LTEP18728356.9T patent/LT3534898T/lt unknown
- 2018-05-30 AU AU2018276382A patent/AU2018276382B2/en active Active
- 2018-05-30 CA CA3061274A patent/CA3061274C/en active Active
- 2018-05-30 KR KR1020197038320A patent/KR102269493B1/ko active IP Right Grant
- 2018-05-30 EA EA201992817A patent/EA201992817A1/ru unknown
- 2018-05-30 US US15/992,529 patent/US10738054B2/en active Active
- 2018-05-30 WO PCT/EP2018/064125 patent/WO2018219977A1/en unknown
- 2018-05-30 PE PE2019002444A patent/PE20200699A1/es unknown
- 2018-05-30 EP EP18728356.9A patent/EP3534898B1/en active Active
-
2019
- 2019-10-17 ZA ZA2019/06863A patent/ZA201906863B/en unknown
- 2019-11-18 PH PH12019502580A patent/PH12019502580B1/en unknown
- 2019-11-21 IL IL270833A patent/IL270833B/en active IP Right Grant
- 2019-11-26 CO CONC2019/0013212A patent/CO2019013212A2/es unknown
- 2019-11-27 NI NI201900122A patent/NI201900122A/es unknown
- 2019-11-29 EC ECSENADI201985426A patent/ECSP19085426A/es unknown
- 2019-11-29 CL CL2019003503A patent/CL2019003503A1/es unknown
-
2020
- 2020-07-01 US US16/918,772 patent/US20200331919A1/en not_active Abandoned
- 2020-10-05 CY CY20201100929T patent/CY1123386T1/el unknown
- 2020-10-07 HR HRP20201608TT patent/HRP20201608T1/hr unknown
- 2020-12-07 JP JP2020202501A patent/JP7157471B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY196526A (en) | Non-Racemic Beta-Hydroxybutyrate Compounds and Compositions Enriched With The R-Enantiomer And Methods Of Use | |
PE20200699A1 (es) | Composiciones sinergicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporcion no racemica | |
CO2021015624A2 (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituída, composiciones de estos y métodos de tratamiento con dichos compuestos | |
AR077252A1 (es) | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos | |
WO2020061486A3 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
PE20200740A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
MX2020012827A (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes. | |
CO6382118A2 (es) | Nuevas octahidrociclopenta(c)ciprol-4aminas sustituidas como bloqueantes de los canales de calcio | |
CL2020001564A1 (es) | Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina. | |
MX2021013576A (es) | Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo. | |
PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
CO2020001881A2 (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco trometamina y clorhidrato de tramadol | |
PH12020551734A1 (en) | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | |
MX2020013707A (es) | Metodos y aplicadores para tratar afecciones vaginales. | |
CO2021007055A2 (es) | Composiciones sinérgicas que comprenden (r)-2-(2-oxopirrolidin-1-il)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporción no racémica | |
MX2020008300A (es) | Uso de [6]-paradol para estabilizacion de composiciones cosmeticas. | |
PH12020551620A1 (en) | Compositions for preventing or treating dry eye | |
MX2022003346A (es) | Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro. | |
PH12021551239A1 (en) | Synergistic compositions comprising r-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones and s-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones in a non-racemic ratio | |
MX2022005912A (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria. |